cell microarray assay Search Results


functional analysis of the 20-cell microarray database  (Broad Institute Inc)
90
Broad Institute Inc functional analysis of the 20-cell microarray database
Functional Analysis Of The 20 Cell Microarray Database, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+microarray+assay/functional+analysis+of+the+20+cell+microarray+database/pmc03776718-56-4-15
Average 90 stars, based on 1 article reviews
functional analysis of the 20-cell microarray database - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
nanomolar synthesis in droplet microarrays with uv-triggered on-chip cell screening  (Verlag GmbH)
90
Verlag GmbH nanomolar synthesis in droplet microarrays with uv-triggered on-chip cell screening
Nanomolar Synthesis In Droplet Microarrays With Uv Triggered On Chip Cell Screening, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+microarray+assay/nanomolar+synthesis+in+droplet+microarrays+with+uv+triggered+on+chip+cell+screening/pm31985878-2-8-3
Average 90 stars, based on 1 article reviews
nanomolar synthesis in droplet microarrays with uv-triggered on-chip cell screening - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mouse oligo gearray osteogenesis microarrays  (SuperArray Bioscience Corporation)
90
SuperArray Bioscience Corporation mouse oligo gearray osteogenesis microarrays
Mouse Oligo Gearray Osteogenesis Microarrays, supplied by SuperArray Bioscience Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+microarray+assay/oligo+gearray+rat+endothelial+cell+biology+microarray/pm18703560-76-16-22
Average 90 stars, based on 1 article reviews
mouse oligo gearray osteogenesis microarrays - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
gearray cell-cycle apoptosis pathway-specific microarrays  (SuperArray Bioscience Corporation)
90
SuperArray Bioscience Corporation gearray cell-cycle apoptosis pathway-specific microarrays
Gearray Cell Cycle Apoptosis Pathway Specific Microarrays, supplied by SuperArray Bioscience Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+microarray+assay/gearray+cell+cycle+apoptosis+pathway+specific+microarrays/10__1186_slash_bcr1893-1609-20-21
Average 90 stars, based on 1 article reviews
gearray cell-cycle apoptosis pathway-specific microarrays - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
chromatin immunoprecipitation combined with promoter microarrays  (Beta Cell Biology Consortium)
90
Beta Cell Biology Consortium chromatin immunoprecipitation combined with promoter microarrays
Chromatin Immunoprecipitation Combined With Promoter Microarrays, supplied by Beta Cell Biology Consortium, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+microarray+assay/chromatin+immunoprecipitation+combined+with+promoter+microarrays/pm16917761-4174-12-16
Average 90 stars, based on 1 article reviews
chromatin immunoprecipitation combined with promoter microarrays - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
cell cycle microarrays  (SuperArray Bioscience Corporation)
90
SuperArray Bioscience Corporation cell cycle microarrays
Cell Cycle Microarrays, supplied by SuperArray Bioscience Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+microarray+assay/cell+cycle+microarrays/pmc01810394-152-0-10
Average 90 stars, based on 1 article reviews
cell cycle microarrays - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tumour tissue microarrays of head and neck squamous cell carcinoma  (Pantomics Inc)
90
Pantomics Inc tumour tissue microarrays of head and neck squamous cell carcinoma
a Relative Ras activity in the immortalised keratinocyte <t>cell</t> line HaCaT and in H-RasV12-transfected HaCaT clones was assayed by the EZ-Detect Ras activation kit. b CCL20 protein production- conditioned medium from HaCaT cells and H-RasV12-transfected HaCaT clones, as detected by a CCL20-specific ELISA. c Activated primary keratinocytes were treated with the selective irreversible inhibitor of EGFR erlotinib, and expression of CCL20 was analysed by qPCR. Tumour cells derived from breast cancer, malignant melanoma and head and <t>neck</t> <t>squamous</t> cell <t>carcinoma</t> (HNSCC) overexpress CCL20. d – f Quantitative real-time PCR analysis of CCL20 in cultured normal primary mammary epithelial cells ( n = 2) and breast cancer cell lines ( n = 7) ( d ), cultured normal primary melanocytes ( n = 2) and melanoma cell lines ( n = 13) ( e ), cultured primary mucosal keratinocytes (KC, n = 2), cell lines derived from primary tumours ( n = 10) or metastases ( n = 4) of HNSCC ( f ). g CCL20 expression of tumour tissues derived from breast cancer (primary breast cancer, n = 12, fc = 1.096; breast cancer metastasis, n = 10, fc = 6.048), malignant melanoma (primary melanoma, n = 28, fc = 4.580; subcutaneous metastasis, n = 11, fc = 6.023; distant metastasis, n = 4, fc = 6.012) and HNSCC (primary tumour, n = 14, fc = 3.057) compared with normal tissue (normal breast, n = 3, cultured primary melanocytes, n = 3, benign nevi, n = 5 and normal oral mucosa, n = 8) by qPCR. Values are either expressed as femtograms of target gene per 25 ng of cDNA or protein concentration in picograms per ml of supernatant and represent the mean ± SD of three independent experiments (* P ≤ 0.05; ** P ≤ 0.01; Mann–Whitney U test).
Tumour Tissue Microarrays Of Head And Neck Squamous Cell Carcinoma, supplied by Pantomics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+microarray+assay/tumour+tissue+microarrays+of+head+and+neck+squamous+cell+carcinoma/pmc07493992-43-9-16
Average 90 stars, based on 1 article reviews
tumour tissue microarrays of head and neck squamous cell carcinoma - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
targeted microarray-based cell-free dna test  (Schmid GmbH)
90
Schmid GmbH targeted microarray-based cell-free dna test
a Relative Ras activity in the immortalised keratinocyte <t>cell</t> line HaCaT and in H-RasV12-transfected HaCaT clones was assayed by the EZ-Detect Ras activation kit. b CCL20 protein production- conditioned medium from HaCaT cells and H-RasV12-transfected HaCaT clones, as detected by a CCL20-specific ELISA. c Activated primary keratinocytes were treated with the selective irreversible inhibitor of EGFR erlotinib, and expression of CCL20 was analysed by qPCR. Tumour cells derived from breast cancer, malignant melanoma and head and <t>neck</t> <t>squamous</t> cell <t>carcinoma</t> (HNSCC) overexpress CCL20. d – f Quantitative real-time PCR analysis of CCL20 in cultured normal primary mammary epithelial cells ( n = 2) and breast cancer cell lines ( n = 7) ( d ), cultured normal primary melanocytes ( n = 2) and melanoma cell lines ( n = 13) ( e ), cultured primary mucosal keratinocytes (KC, n = 2), cell lines derived from primary tumours ( n = 10) or metastases ( n = 4) of HNSCC ( f ). g CCL20 expression of tumour tissues derived from breast cancer (primary breast cancer, n = 12, fc = 1.096; breast cancer metastasis, n = 10, fc = 6.048), malignant melanoma (primary melanoma, n = 28, fc = 4.580; subcutaneous metastasis, n = 11, fc = 6.023; distant metastasis, n = 4, fc = 6.012) and HNSCC (primary tumour, n = 14, fc = 3.057) compared with normal tissue (normal breast, n = 3, cultured primary melanocytes, n = 3, benign nevi, n = 5 and normal oral mucosa, n = 8) by qPCR. Values are either expressed as femtograms of target gene per 25 ng of cDNA or protein concentration in picograms per ml of supernatant and represent the mean ± SD of three independent experiments (* P ≤ 0.05; ** P ≤ 0.01; Mann–Whitney U test).
Targeted Microarray Based Cell Free Dna Test, supplied by Schmid GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+microarray+assay/targeted+microarray+based+cell+free+dna+test/10__1159_slash_000495091-71-44-47
Average 90 stars, based on 1 article reviews
targeted microarray-based cell-free dna test - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
apoptosis/cell cycle-specific microarray  (SuperArray Bioscience Corporation)
90
SuperArray Bioscience Corporation apoptosis/cell cycle-specific microarray
a Relative Ras activity in the immortalised keratinocyte <t>cell</t> line HaCaT and in H-RasV12-transfected HaCaT clones was assayed by the EZ-Detect Ras activation kit. b CCL20 protein production- conditioned medium from HaCaT cells and H-RasV12-transfected HaCaT clones, as detected by a CCL20-specific ELISA. c Activated primary keratinocytes were treated with the selective irreversible inhibitor of EGFR erlotinib, and expression of CCL20 was analysed by qPCR. Tumour cells derived from breast cancer, malignant melanoma and head and <t>neck</t> <t>squamous</t> cell <t>carcinoma</t> (HNSCC) overexpress CCL20. d – f Quantitative real-time PCR analysis of CCL20 in cultured normal primary mammary epithelial cells ( n = 2) and breast cancer cell lines ( n = 7) ( d ), cultured normal primary melanocytes ( n = 2) and melanoma cell lines ( n = 13) ( e ), cultured primary mucosal keratinocytes (KC, n = 2), cell lines derived from primary tumours ( n = 10) or metastases ( n = 4) of HNSCC ( f ). g CCL20 expression of tumour tissues derived from breast cancer (primary breast cancer, n = 12, fc = 1.096; breast cancer metastasis, n = 10, fc = 6.048), malignant melanoma (primary melanoma, n = 28, fc = 4.580; subcutaneous metastasis, n = 11, fc = 6.023; distant metastasis, n = 4, fc = 6.012) and HNSCC (primary tumour, n = 14, fc = 3.057) compared with normal tissue (normal breast, n = 3, cultured primary melanocytes, n = 3, benign nevi, n = 5 and normal oral mucosa, n = 8) by qPCR. Values are either expressed as femtograms of target gene per 25 ng of cDNA or protein concentration in picograms per ml of supernatant and represent the mean ± SD of three independent experiments (* P ≤ 0.05; ** P ≤ 0.01; Mann–Whitney U test).
Apoptosis/Cell Cycle Specific Microarray, supplied by SuperArray Bioscience Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+microarray+assay/apoptosis+cell+cycle+specific+microarray/pm16380976-90-13-16
Average 90 stars, based on 1 article reviews
apoptosis/cell cycle-specific microarray - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
living-cell microarrays  (Living Cell Technologies Inc)
90
Living Cell Technologies Inc living-cell microarrays
a Relative Ras activity in the immortalised keratinocyte <t>cell</t> line HaCaT and in H-RasV12-transfected HaCaT clones was assayed by the EZ-Detect Ras activation kit. b CCL20 protein production- conditioned medium from HaCaT cells and H-RasV12-transfected HaCaT clones, as detected by a CCL20-specific ELISA. c Activated primary keratinocytes were treated with the selective irreversible inhibitor of EGFR erlotinib, and expression of CCL20 was analysed by qPCR. Tumour cells derived from breast cancer, malignant melanoma and head and <t>neck</t> <t>squamous</t> cell <t>carcinoma</t> (HNSCC) overexpress CCL20. d – f Quantitative real-time PCR analysis of CCL20 in cultured normal primary mammary epithelial cells ( n = 2) and breast cancer cell lines ( n = 7) ( d ), cultured normal primary melanocytes ( n = 2) and melanoma cell lines ( n = 13) ( e ), cultured primary mucosal keratinocytes (KC, n = 2), cell lines derived from primary tumours ( n = 10) or metastases ( n = 4) of HNSCC ( f ). g CCL20 expression of tumour tissues derived from breast cancer (primary breast cancer, n = 12, fc = 1.096; breast cancer metastasis, n = 10, fc = 6.048), malignant melanoma (primary melanoma, n = 28, fc = 4.580; subcutaneous metastasis, n = 11, fc = 6.023; distant metastasis, n = 4, fc = 6.012) and HNSCC (primary tumour, n = 14, fc = 3.057) compared with normal tissue (normal breast, n = 3, cultured primary melanocytes, n = 3, benign nevi, n = 5 and normal oral mucosa, n = 8) by qPCR. Values are either expressed as femtograms of target gene per 25 ng of cDNA or protein concentration in picograms per ml of supernatant and represent the mean ± SD of three independent experiments (* P ≤ 0.05; ** P ≤ 0.01; Mann–Whitney U test).
Living Cell Microarrays, supplied by Living Cell Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+microarray+assay/living+cell+microarrays/us09447446-474-3-6
Average 90 stars, based on 1 article reviews
living-cell microarrays - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mouse cell surface markers microarray  (SuperArray Bioscience Corporation)
90
SuperArray Bioscience Corporation mouse cell surface markers microarray
a Relative Ras activity in the immortalised keratinocyte <t>cell</t> line HaCaT and in H-RasV12-transfected HaCaT clones was assayed by the EZ-Detect Ras activation kit. b CCL20 protein production- conditioned medium from HaCaT cells and H-RasV12-transfected HaCaT clones, as detected by a CCL20-specific ELISA. c Activated primary keratinocytes were treated with the selective irreversible inhibitor of EGFR erlotinib, and expression of CCL20 was analysed by qPCR. Tumour cells derived from breast cancer, malignant melanoma and head and <t>neck</t> <t>squamous</t> cell <t>carcinoma</t> (HNSCC) overexpress CCL20. d – f Quantitative real-time PCR analysis of CCL20 in cultured normal primary mammary epithelial cells ( n = 2) and breast cancer cell lines ( n = 7) ( d ), cultured normal primary melanocytes ( n = 2) and melanoma cell lines ( n = 13) ( e ), cultured primary mucosal keratinocytes (KC, n = 2), cell lines derived from primary tumours ( n = 10) or metastases ( n = 4) of HNSCC ( f ). g CCL20 expression of tumour tissues derived from breast cancer (primary breast cancer, n = 12, fc = 1.096; breast cancer metastasis, n = 10, fc = 6.048), malignant melanoma (primary melanoma, n = 28, fc = 4.580; subcutaneous metastasis, n = 11, fc = 6.023; distant metastasis, n = 4, fc = 6.012) and HNSCC (primary tumour, n = 14, fc = 3.057) compared with normal tissue (normal breast, n = 3, cultured primary melanocytes, n = 3, benign nevi, n = 5 and normal oral mucosa, n = 8) by qPCR. Values are either expressed as femtograms of target gene per 25 ng of cDNA or protein concentration in picograms per ml of supernatant and represent the mean ± SD of three independent experiments (* P ≤ 0.05; ** P ≤ 0.01; Mann–Whitney U test).
Mouse Cell Surface Markers Microarray, supplied by SuperArray Bioscience Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+microarray+assay/mouse+cell+surface+markers+microarray/pmc03217318-90-33-15
Average 90 stars, based on 1 article reviews
mouse cell surface markers microarray - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
cell microarray chip  (Starlight Co Ltd)
90
Starlight Co Ltd cell microarray chip
a Relative Ras activity in the immortalised keratinocyte <t>cell</t> line HaCaT and in H-RasV12-transfected HaCaT clones was assayed by the EZ-Detect Ras activation kit. b CCL20 protein production- conditioned medium from HaCaT cells and H-RasV12-transfected HaCaT clones, as detected by a CCL20-specific ELISA. c Activated primary keratinocytes were treated with the selective irreversible inhibitor of EGFR erlotinib, and expression of CCL20 was analysed by qPCR. Tumour cells derived from breast cancer, malignant melanoma and head and <t>neck</t> <t>squamous</t> cell <t>carcinoma</t> (HNSCC) overexpress CCL20. d – f Quantitative real-time PCR analysis of CCL20 in cultured normal primary mammary epithelial cells ( n = 2) and breast cancer cell lines ( n = 7) ( d ), cultured normal primary melanocytes ( n = 2) and melanoma cell lines ( n = 13) ( e ), cultured primary mucosal keratinocytes (KC, n = 2), cell lines derived from primary tumours ( n = 10) or metastases ( n = 4) of HNSCC ( f ). g CCL20 expression of tumour tissues derived from breast cancer (primary breast cancer, n = 12, fc = 1.096; breast cancer metastasis, n = 10, fc = 6.048), malignant melanoma (primary melanoma, n = 28, fc = 4.580; subcutaneous metastasis, n = 11, fc = 6.023; distant metastasis, n = 4, fc = 6.012) and HNSCC (primary tumour, n = 14, fc = 3.057) compared with normal tissue (normal breast, n = 3, cultured primary melanocytes, n = 3, benign nevi, n = 5 and normal oral mucosa, n = 8) by qPCR. Values are either expressed as femtograms of target gene per 25 ng of cDNA or protein concentration in picograms per ml of supernatant and represent the mean ± SD of three independent experiments (* P ≤ 0.05; ** P ≤ 0.01; Mann–Whitney U test).
Cell Microarray Chip, supplied by Starlight Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+microarray+assay/cell+microarray+chip/pm22396762-51-12-42
Average 90 stars, based on 1 article reviews
cell microarray chip - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


a Relative Ras activity in the immortalised keratinocyte cell line HaCaT and in H-RasV12-transfected HaCaT clones was assayed by the EZ-Detect Ras activation kit. b CCL20 protein production- conditioned medium from HaCaT cells and H-RasV12-transfected HaCaT clones, as detected by a CCL20-specific ELISA. c Activated primary keratinocytes were treated with the selective irreversible inhibitor of EGFR erlotinib, and expression of CCL20 was analysed by qPCR. Tumour cells derived from breast cancer, malignant melanoma and head and neck squamous cell carcinoma (HNSCC) overexpress CCL20. d – f Quantitative real-time PCR analysis of CCL20 in cultured normal primary mammary epithelial cells ( n = 2) and breast cancer cell lines ( n = 7) ( d ), cultured normal primary melanocytes ( n = 2) and melanoma cell lines ( n = 13) ( e ), cultured primary mucosal keratinocytes (KC, n = 2), cell lines derived from primary tumours ( n = 10) or metastases ( n = 4) of HNSCC ( f ). g CCL20 expression of tumour tissues derived from breast cancer (primary breast cancer, n = 12, fc = 1.096; breast cancer metastasis, n = 10, fc = 6.048), malignant melanoma (primary melanoma, n = 28, fc = 4.580; subcutaneous metastasis, n = 11, fc = 6.023; distant metastasis, n = 4, fc = 6.012) and HNSCC (primary tumour, n = 14, fc = 3.057) compared with normal tissue (normal breast, n = 3, cultured primary melanocytes, n = 3, benign nevi, n = 5 and normal oral mucosa, n = 8) by qPCR. Values are either expressed as femtograms of target gene per 25 ng of cDNA or protein concentration in picograms per ml of supernatant and represent the mean ± SD of three independent experiments (* P ≤ 0.05; ** P ≤ 0.01; Mann–Whitney U test).

Journal: British Journal of Cancer

Article Title: EGFR/Ras-induced CCL20 production modulates the tumour microenvironment

doi: 10.1038/s41416-020-0943-2

Figure Lengend Snippet: a Relative Ras activity in the immortalised keratinocyte cell line HaCaT and in H-RasV12-transfected HaCaT clones was assayed by the EZ-Detect Ras activation kit. b CCL20 protein production- conditioned medium from HaCaT cells and H-RasV12-transfected HaCaT clones, as detected by a CCL20-specific ELISA. c Activated primary keratinocytes were treated with the selective irreversible inhibitor of EGFR erlotinib, and expression of CCL20 was analysed by qPCR. Tumour cells derived from breast cancer, malignant melanoma and head and neck squamous cell carcinoma (HNSCC) overexpress CCL20. d – f Quantitative real-time PCR analysis of CCL20 in cultured normal primary mammary epithelial cells ( n = 2) and breast cancer cell lines ( n = 7) ( d ), cultured normal primary melanocytes ( n = 2) and melanoma cell lines ( n = 13) ( e ), cultured primary mucosal keratinocytes (KC, n = 2), cell lines derived from primary tumours ( n = 10) or metastases ( n = 4) of HNSCC ( f ). g CCL20 expression of tumour tissues derived from breast cancer (primary breast cancer, n = 12, fc = 1.096; breast cancer metastasis, n = 10, fc = 6.048), malignant melanoma (primary melanoma, n = 28, fc = 4.580; subcutaneous metastasis, n = 11, fc = 6.023; distant metastasis, n = 4, fc = 6.012) and HNSCC (primary tumour, n = 14, fc = 3.057) compared with normal tissue (normal breast, n = 3, cultured primary melanocytes, n = 3, benign nevi, n = 5 and normal oral mucosa, n = 8) by qPCR. Values are either expressed as femtograms of target gene per 25 ng of cDNA or protein concentration in picograms per ml of supernatant and represent the mean ± SD of three independent experiments (* P ≤ 0.05; ** P ≤ 0.01; Mann–Whitney U test).

Article Snippet: Tumour tissue microarrays of breast cancer and head and neck squamous cell carcinoma were acquired from Pantomics, Inc. (San Francisco, CA, USA), Super Bio Chips (Seoul, Korea) and US Biomax, Inc. (Rockville, MD, USA).

Techniques: Activity Assay, Transfection, Clone Assay, Activation Assay, Enzyme-linked Immunosorbent Assay, Expressing, Derivative Assay, Real-time Polymerase Chain Reaction, Cell Culture, Protein Concentration, MANN-WHITNEY